On Thursday, Rhythm Pharmaceuticals hit an important technical milestone, with its Relative Strength (RS) Rating rising into the 80-plus percentile with an improvement to 82, a rise from 78 the day before.
This exclusive rating from Investor's Business Daily tracks share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the top-performing stocks tend to have an RS Rating of above 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Rhythm Pharmaceuticals is working on a consolidation with a 68.58 buy point. See if the stock can break out in volume at least 40% above average.
Rhythm Pharmaceuticals reported 0% earnings growth last quarter. Revenue rose 48%. Keep an eye out for the company's next round of numbers on or around Mar. 4.
Rhythm Pharmaceuticals holds the No. 59 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and United Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
